KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Other Non-Current Liabilities data on record, last reported at $2.0 billion in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 28.47% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, up 28.47%, while the annual FY2025 figure was $2.0 billion, 28.47% up from the prior year.
  • Other Non-Current Liabilities reached $2.0 billion in Q4 2025 per REGN's latest filing, up from $1.9 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.0 billion in Q4 2025 and bottomed at $43.7 million in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $1.0 billion, with a median of $724.7 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 92.7% in 2023, then skyrocketed 3432.27% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $662.6 million in 2021, then fell by 3.71% to $638.0 million in 2022, then skyrocketed by 33.87% to $854.1 million in 2023, then skyrocketed by 83.98% to $1.6 billion in 2024, then grew by 28.47% to $2.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $2.0 billion in Q4 2025, $1.9 billion in Q3 2025, and $1.7 billion in Q2 2025.